임상 레이더 AI | ||
|---|---|---|
임상시험 NCT06573593은(는) 원형 탈모증, Janus Kinase Inhibitors에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study 150 리얼월드 데이터
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT06573593은(는) 원형 탈모증, Janus Kinase Inhibitors에 대해 알아보는 관찰연구입니다. 현재 상태는 모집중이며, 연구는 2024년 7월 29일에 시작되어 150명의 참여자를 모집하고 있습니다. Second Affiliated Hospital, School of Medicine, Zhejiang University이(가) 진행하며, 2026년 12월 31일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2024년 8월 27일에 갱신되었습니다.
간단한 개요
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disea...더 보기
공식 제목
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
질환명
원형 탈모증Janus Kinase Inhibitors기타 연구 식별자
- 20240699
NCT 번호
실제 연구 시작일
2024-07-29
최신 업데이트 게시
2024-08-27
예상 연구 완료일
2026-12-31
계획된 등록 인원
150
연구종류
관찰연구
상태
모집중
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
Tofacitinib treated group In the real-world settings, patients with AA treated with tofacitinib. | Tofacitinib In the real-world settings, patients with AA treated with tofacitinib. |
Baritinib treated group In the real-world settings, patients with AA treated with baritinib. | Baricitinib In the real-world settings, patients with AA treated with Baricitinib. |
Ruxolitinib treated group In the real-world settings, patients with AA treated with ruxolitinib | 룩솔리티닙 In the real-world settings, patients with AA treated with Ruxolitinib. |
Upadacitinib treated group In the real-world settings, patients with AA treated with upadacitinib. | 우파다시티닙 In the real-world settings, patients with AA treated with Upadacitinib. |
Abrocitinib treated group In the real-world settings, patients with AA treated with abhicitinib. | Abrocitinib In the real-world settings, patients with AA treated with Abrocitinib. |
Ritlecitinib treated group In the real-world settings, patients with AA treated with ritlecitinib. | Ritlecitinib In the real-world settings, patients with AA treated with Ritlecitinib. |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Mean SALT | Reduction of Severity of Alopecia Tool (SALT) score compared with baseline | at week 24 |
SALT50 | Percentage of patient with more than 50% improvement in SALT score | at week 24 |
SALT75 | Percentage of patient with more than 70% improvement in SALT score | at week 24 |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Mean SALT | Reduction of Severity of Alopecia Tool (SALT) score compared with baseline | at week 12, 36, 48, 56 |
SALT50 | Percentage of patient with more than 75% improvement in SALT score | at week 12, 36, 48, 56 |
SALT75 | Percentage of patient with more than 50% improvement in SALT score | at week 12, 36, 48, 56 |
Safety profile | Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events. | at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 |
참여 도우미
적격성 기준
연령대
어린이, 성인, 노인
최소 연령
2 Years
참여 가능한 성별
전체
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
- Patients had previously received hair implants
- Other alopecia
- Other diseases may induce alopecia including psoriasis, lichen planus, et al.
- Unable to estimate SALT score at baseline or at follow-up
- Patients are participating in other clinical trials
Second Affiliated Hospital, School of Medicine, Zhejiang University연구 대표 연락처
연락처: Ru Dai, MD, 15982215914, [email protected]
연락처: Wu, [email protected]
1 1개국에 임상시험 장소
Zhejiang
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, 310009, China
Ru Dai, Ph.D, 연락처, 86 15982215914, [email protected]
모집중